To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Ann Arbor staging
Ann Arbor staging is the staging system for lymphomas, both in Hodgkin's lymphoma (previously called Hodgkin's Disease) and Non-Hodgkin lymphoma (abbreviated NHL). It was initially developed for Hodgkin's, but has some use in NHL. It has roughly the same function as TNM staging in solid tumors.
The stage depends on both the place where the malignant tissue is located (as located with biopsy, CT scanning and increasingly positron emission tomography) and on systemic symptoms due to the lymphoma ("B symptoms": night sweats, weight loss of >10% or fevers).
Additional recommended knowledge
The principal stage is determined by location of the tumor:
These letters can be appended to some stages:
Type of staging
The nature of the staging is (occasionally) expressed with:
The staging does not take into account the grade (biological behavior) of the tumor tissue. The prognostic significance of bulky disease, and some other modifiers, were introduced with the "Cotswolds modification" (Lister et al 1989).
The Ann Arbor classification is named after Ann Arbor, Michigan, where the Committee on Hodgkin's Disease Staging Classification met in 1971; it consisted of experts from the USA, UK, Germany and France, and replaced the older Rye classification from a 1965 meeting (Rosenberg 1966). The Cotswolds modification followed after a 1988 meeting in the UK Cotswolds. 
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ann_Arbor_staging". A list of authors is available in Wikipedia.|